2023-04-21
Continued momentum in mRNA vaccines and therapeutics with over 840 programs under development, according to fresh data from Beacon RNA database by Hanson Wade. Limitations of hitherto dominant lipid nanoparticle (LNP) technologies call for alternate mRNA delivery solutions. Altamira's peptide-based SemaPhore™ nanoparticle technology confers great stability to mRNA, is non-immunogenic and...